SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells

Capozzi VA, Rosati A, Turco LC, Sozzi G, Ricco M, Chiofalo B, Vizzielli G. Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option. Gland Surg. 2020;9:1112–7.

Article  Google Scholar 

Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014;290:1067–78.

CAS  Article  Google Scholar 

Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28:viii13–5.

CAS  Article  Google Scholar 

Westin SN, Louie-Gao M, Gupta D, Thaker PH. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. Future Oncol. 2021;17:4263–74.

CAS  Article  Google Scholar 

Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinumbased chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022;47:1–11.

Google Scholar 

Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, Kalkkinen N, Kieff E, Silvennoinen O. Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J. 2002;21:4950–8.

CAS  Article  Google Scholar 

Yang J, Valineva T, Hong J, Bu T, Yao Z, Jensen ON, Frilander MJ, Silvennoinen O. Transcriptional co-activator protein p100 interacts with snRNP proteins and facilitates the assembly of the spliceosome. Nucleic Acids Res. 2007;35:4485–94.

CAS  Article  Google Scholar 

Gao X, Zhao X, Zhu Y, He J, Shao J, Su C, Zhang Y, Zhang W, Saarikettu J, Silvennoinen O, Yao Z, Yang J. Tudor staphylococcal nuclease (Tudor-SN) participates in small ribonucleoprotein (snRNP) assembly via interacting with symmetrically dimethylated Sm proteins. J Biol Chem. 2012;287:18130–41.

CAS  Article  Google Scholar 

Su C, Zhang C, Tecle A, Fu X, He J, Song J, Zhang W, Sun X, Ren Y, Silvennoinen O, Yao Z, Yang X, Wei M, Yang J. Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F–1 in cell cycle regulation. J Biol Chem. 2015;290:7208–20.

CAS  Article  Google Scholar 

Elbarbary RA, Miyoshi K, Myers JR, Du P, Ashton JM, Tian B, Maquat LE. Tudor-SN–mediated endonucleolytic decay of human cell microRNAs promotes G1/S phase transition. Science. 2017;356:859–62.

CAS  Article  Google Scholar 

Fu X, Zhang C, Meng H, Zhang K, Shi L, Cao C, Wang Y, Su C, Xin L, Ren Y, Zhang W, Sun X, Ge L, Silvennoinen O, Yao Z, Yang X, Yang J. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. Cell Death Differ. 2018;25:1625–37.

CAS  Article  Google Scholar 

Sundstrom JF, Vaculova A, Smertenko AP, Savenkov EI, Golovko A, Minina E, Tiwari BS, Rodriguez-Nieto S, Zamyatnin AA, Valineva T, Saarikettu J, Frilander MJ, Suarez MF, Zavialov A, Stahl U, Hussey PJ, Silvennoinen O, Sundberg E, Zhivotovsky B, Bozhkov PV. Tudor staphylococcal nuclease is an evolutionarily conserved component of the programmed cell death degradome. Nat Cell Biol. 2009;11:1347-U1198.

Article  Google Scholar 

Duan Z, Zhao X, Fu X, Su C, Xin L, Saarikettu J, Yang X, Yao Z, Silvennoinen O, Wei M, Yang J. Tudor-SN, a novel coactivator of peroxisome proliferator-activated receptor gamma protein, is essential for adipogenesis. J Biol Chem. 2014;289:8364–74.

CAS  Article  Google Scholar 

Yu L, Di Y, Xin L, Ren Y, Liu X, Sun X, Zhang W, Yao Z, Yang J. SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis. Oncogene. 2017;36:3903–14.

CAS  Article  Google Scholar 

Cui XT, Zhang XX, Liu MH, Zhao CY, Zhang N, Ren YY, Su C, Zhang W, Sun XM, He JY, Gao XJ, Yang J. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020;112:3958–67.

CAS  Article  Google Scholar 

Gao X, Ge L, Shao J, Su C, Zhao H, Saarikettu J, Yao X, Yao Z, Silvennoinen O, Yang J. Tudor-SN interacts with and co-localizes with G3BP in stress granules under stress conditions. FEBS Lett. 2010;584:3525–32.

CAS  Article  Google Scholar 

Su C, Gao X, Yang W, Zhao Y, Fu X, Cui X, Zhang C, Xin L, Ren Y, Li L, Shui W, Yang X, Wei M, Yang J. Phosphorylation of Tudor-SN, a novel substrate of JNK, is involved in the efficient recruitment of Tudor-SN into stress granules. Biochim Biophys Acta (BBA) – Mol Cell Res. 2017;1864:562–71.

CAS  Article  Google Scholar 

Cui XT, Zhao CY, Yao XY, Qian BX, Su C, Ren YY, Yao Z, Gao XJ, Yang J. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. RNA Biol. 2018;15:1364–75.

Article  Google Scholar 

Wang Y, Wang XT, Cui XT, Zhuo Y, Li HS, Ha CB, Xin LB, Ren YY, Zhang W, Sun XM, Ge L, Liu X, He JY, Zhang T, Zhang K, Yao Z, Yang X, Yang J. Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8(+) T cell response in tumor. Sci Adv. 2020. https://doi.org/10.1126/sciadv.aba5412.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Zhang C, Wang S, Rashu R, Thomas R, Yang J, Yang X. SND1 promotes Th1/17 immunity against chlamydial lung infection through enhancing dendritic cell function. PLoS Pathog. 2021;17:e1009295.

Article  Google Scholar 

Wu G, Ma Z, Hu W, Wang D, Gong B, Fan C, Jiang S, Li T, Gao J, Yang Y. Molecular insights of Gas6/TAM in cancer development and therapy. Cell Death Dis. 2017;8:e2700.

Article  Google Scholar 

Mullen MM, Lomonosova E, Toboni MD, Oplt A, Cybulla E, Blachut B, Zhao P, Noia H, Wilke D, Rankin EB, Kuroki LM, Hagemann AR, Hagemann IS, McCourt CK, Thaker PH, Mutch DG, Powell MA, Mosammaparast N, Vindigni A, Fuh KC. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Mol Cancer Res. 2022;20:265–79.

CAS  Article  Google Scholar 

Mao S, Wu Y, Wang R, Guo Y, Bi D, Ma W, Zhang W, Zhang J, Yan Y, Yao X. Overexpression of GAS6 promotes cell proliferation and invasion in bladder cancer by activation of the PI3K/AKT pathway. Onco Targets Ther. 2020;13:4813–24.

CAS  Article  Google Scholar 

Xin LB, Zhao R, Lei J, Song JC, Yu L, Gao R, Ha CB, Ren YY, Liu X, Liu YX, Yao Z, Yang J. SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB J. 2019;33:3795–806.

CAS  Article  Google Scholar 

Saarikettu J, Ovod V, Vuoksio M, Gronholm J, Yang J, Silvennoinen O. Monoclonal antibodies against human tudor-SN. Hybridoma. 2010;29:231–6.

CAS  Article  Google Scholar 

Liu L, Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: a systematic review and meta-analysis. Medicine. 2021;100:e26849.

CAS  Article  Google Scholar 

Tanaka M, Siemann DW. Therapeutic targeting of the Gas6/Axl signaling pathway in cancer. Int J Mol Sci. 2021;22:9953.

CAS  Article  Google Scholar 

Di Stasi R, De Rosa L, D’Andrea LD. Therapeutic aspects of the Axl/Gas6 molecular system. Drug Discov Today. 2020;25:2130–48.

Article  Google Scholar 

留言 (0)

沒有登入
gif